NEW DELHI – An increasing number of Chinese and Indian pharma firms are setting up units in each other's countries, looking to tap into expertise and strength that may be lacking at home.
NEW DELHI – An increasing number of Chinese and Indian pharma firms are setting up units in each other’s countries, looking to tap into expertise and strength that may be lacking at home.
NEW DELHI – India's Lee Pharma Ltd. may not be granted a compulsory license to manufacture a patented diabetes drug, with the patent regulator suggesting the company has not made a strong enough case for such a license.
NEW DELHI – Yet another Indian contract research organization (CRO), Hyderabad-based Sipra Labs Ltd., has found itself in hot water after the U.S. FDA issued a warning letter over flaws detected in analytical procedures.
NEW DELHI – Yet another Indian contract research organization (CRO), Hyderabad-based Sipra Labs Ltd., has found itself in hot water after the U.S. FDA issued a warning letter over flaws detected in analytical procedures.
NEW DELHI – India's Lee Pharma Ltd. may not be granted a compulsory license to manufacture a patented diabetes drug, with the patent regulator suggesting the company has not made a strong enough case for such a license.
NEW DELHI – India deferred its talks with the European Union on a broad-based investment trade agreement "for the present, in response to the European Commission's [EC's] July ban on 700 Indian generics." Trade talks between the EU and India were to resume in August, after a gap of two years.
NEW DELHI – India deferred its talks with the European Union on a broad-based investment trade agreement "for the present, in response to the European Commission's [EC's] July ban on 700 Indian generics." Trade talks between the EU and India were to resume in August, after a gap of two years.
NEW DELHI – In a move that could cost India's generics industry more than $1 billion, the European Commission (EC) has banned 700 Indian generic drugs, based on flaws detected during inspections of clinical trials conducted by Hyderabad-based contract research organization GVK Biosciences Ltd. The flaws pertained mainly to "data manipulations" of electrocardiograms conducted of patients during studies on several generic medicines. (See BioWorld Today, Feb. 4, 2015.)
NEW DELHI – In a move that could cost India's generics industry more than $1 billion, the European Commission (EC) has banned 700 Indian generic drugs, based on flaws detected during inspections of clinical trials conducted by Hyderabad-based contract research organization GVK Biosciences Ltd.
